Hanall Biopharma Co., Ltd.

Daewoong Co., Ltd.

Goldstar Electron Co., Ltd.

Goldstar, Co., Ltd.

Seung Kook Park

Eun Sun Kim

Sung Wuk Kim

Jae Kap Jeong

Yeon Jung Song

Hyea Kyung Ahn

Song Young Kim

Dongok Shin

Min Sun Kim

Hae-Young Yong

Ha Na Kim

Sung Soo Jun

Tae Hyoung Yoo

Sang Kil Lee

Chae Ha Yoon

Sang Wook Lee

Yo Kyung Chung

Joon Pio Hong

Byung Hoon Min

Jae Young Chang

Bong Yong Lee

Kyeong Sun Shin

Kyung Hyun Min

Tae Hee Lee

Min Suk Lee

Won Chul Kim

Oh Byung Kwon

Young Ju Kim

Yoon Seok Lee

Shin Hye Park

Tai Young Koo

Sun Hee Kim

Hung Keun Lee

Jeong Haing Heo

The present disclosure relates to an isolated anti-FcRn antibody, which is an antibody binding to FcRn (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.

Antibody binding to FCRN for treating autoimmune diseases

Antibody binding to FcRn for treating autoimmune diseases

The present invention relates to a human antibody specific for FcRn that is a receptor with a high affinity for IgG, a production method thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune disease using the same. The FcRn-specific antibody according to the present invention can bind to FcRn non-competitively with IgG or the like to reduce serum auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.

FcRn-specific human antibody and composition for treatment of autoimmune diseases

The present invention relates to new uses of modified human tumor necrosis factor receptor-1 (TNFRI) polypeptide, and more particularly, to uses thereof for prevention and treatment of dry eye syndrome. The modified TNFRI or modified TNFRI fragment of the present invention has excellent TNF&#x3b1; neutralizing activity, and inhibits TNF&#x3b1; activity on the ocular surface of the patient to suppress inflammation induction effects related to dry eye. Therefore, the modified TNFRI or modified TNFRI fragment of the present invention exhibits remarkable effects in the prevention and treatment of dry eye syndrome, and thus can be very useful in the prevention and treatment of dry eye syndrome.

Uses of modified human tumor necrosis factor receptor-1 polypeptide

The present invention relates to a modified human tumor necrosis factor receptor-1 polypeptide to be coupled to a tumor necrosis factor in vivo or ex vivo, or to a fragment thereof. The modified human tumor necrosis factor receptor-1 polypeptide or the fragment thereof according to the present invention exhibit improved resistance against in vivo protease activity, and thus exhibit improved bioavailability and an improved absorption rate.

Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing same

The present invention relates to a modified human tumor necrosis factor receptor-1 polypeptide which is capable of binding to a tumor necrosis factor in vivo or ex vivo, or to a fragment thereof. The modified human tumor necrosis factor receptor-1 polypeptide or the fragment thereof according to the present invention exhibit improved binding affinity to the tumor necrosis factor.

Modified human tumor necrosis factor receptor-I polypeptide or fragment thereof, and method for preparing same

Provided is a modified human tumor necrosis factor receptor-1 polypeptide or a fragment thereof that binds to a tumor necrosis factor in vivo or ex vivo. The modified human tumor necrosis factor receptor-1 polypeptide or fragment exhibits improved ability to bind tumor necrosis factor and resistance to proteases.

The present invention relates to a nanoliposome comprising a liposome membrane containing esterified lecithin, and one or more physiologically active ingredients included in inner space of the liposome membrane; a method for preparing the same; and a composition for preventing or treating skin diseases, comprising the same. The nanoliposome according to the present invention has long-term stability and uniformity, and so can be used to prepare a composition for skin having excellent moisturizing and penetrating properties, such as cosmetics, medicament for treating skin diseases, or the like. In particular, the present composition for preventing or treating skin diseases comprises epidermal growth factor included in the nanoliposome, thereby showing an excellent effect of stimulating skin-penetration and good pharmaceutical stability. Also, the esterified lecithin used in preparing liposome can provide effects of softening skin and stimulating skin-penetration, thereby enhancing the penetration of epidermal growth factor and natural extract into skin, as well as additional moisturizing effect which is advantageous in treating skin diseases. Further, since the present composition comprises nanoliposome prepared by containing esterified lecithin in liposome membrane, the conventional problems of heating and dispersing active ingredients at high temperature (70&#xb0; C. or more), low stability and uniformity, or the like can be solved.

Nanoliposome using esterified lecithin and method for preparing the same, and composition for preventing or treating skin diseases comprising the same

Disclosed herein is a stable liquid formulation comprising human growth hormone; L-lysine, L-arginine or polyethylene glycol 300; and poly(oxyethylene) poly(oxypropylene) copolymer, polyethylene glycol-15 polyoxystearate or polyethylene glycol-35 castor oil.

Stable liquid formulation of human growth hormone

Disclosed are a method of producing a target protein in a biologically-active, soluble form in prokaryotic cells and polycistronic vectors therefor.

Preparation method for the production of active and soluble proteins in prokaryotes and polycistronic vectors therefor

A reference voltage generator includes a current mirror circuit connected to a power supply voltage and having a plurality of transistors which are coupled in parallel to the power supply voltage, a reference current circuit connected between the current mirror circuit and a ground for generating a reference current in accordance with an differential operation, a feedback circuit for applying the reference current to the current mirror circuit, and a constant voltage circuit having an operational amplifier whose input terminal is connected to the current mirror circuit for generating the reference voltage.

Temperature stabilized low reference voltage generator

A sensorless and brushless DC motor in which phase-corresponding coils are turned on at an electric angle of 180.degree.. The driving circuit of the DC motor includes comparators for outputting position detection signals, comparators for outputting turn-on signals, power transistors for turning on phase-corresponding coils, a rotation direction control section, a charge/discharge control section, a charge/discharge section, a turn-off signal generating section, and transistors for forcedly turning off the power transistors.

Driving methods and driving circuits for brushless DC motors without

Growing community of inventors

Seoul, South Korea

Seung Kook Park